A Phase 2/3 interventional study of rMenB+OMV NZ and Placebo in Meningococcal Disease, sponsored by Novartis Vaccines. Completed at 10 sites in Chile. Open to participants aged 11 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-20.
Sponsored by Novartis Vaccines (formerly part of Novartis) · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies testing 4CMenB vaccine in Meningococcal Infections — 1 open to participants now, 2 under way, none of them phase 3. 4CMenB vaccine · Meningococcal Infections.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 2 in phase 2/3, and was the 3rd registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →1 of the 21 studies testing 4CMenB vaccine in Meningococcal Infections is open now, in 1 country. Recruiting first, the newest first:
Medical University of Vienna · Sites in Austria
Ages 18–60 · Healthy volunteers
By country, each count listing its studies:
4CMenB vaccine: first FDA approval 2014 (Trumenba). What it is approved for, and how studies give it, is on its page →
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 11 Years to 17 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 9 · Phase 4 4
First in 2006; this study’s year is marked. 2 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,631 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 508 across the 21 interventional studies. Of the 19 that completed or were terminated, 15 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 21 have an industry lead sponsor. The 7 most frequent:
This study is registered under Novartis Vaccines, one of the names counted as Novartis. Under that name alone:
Novartis Vaccines is the lead sponsor of 165 studies on the registry; none are open to participants now.
60 studies in Meningococcal Infections by Novartis: none open now, none under way, none of them phase 3. Of 59 finished, 48 (81%) have results posted.
Among the 60 studies in Meningococcal Infections by Novartis, this one is the 9th largest by enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2008, is one of 3 in phase 2/3, and was the 25th registered.
Novartis’s Meningococcal Infections studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 21 studies testing 4CMenB vaccine in Meningococcal Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 60 in Meningococcal Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The proposed study is aimed to assess the antibody response and short-term persistence of Novartis Meningococcal B Vaccine after one, two or three doses and to evaluate the optimal vaccination schedule in an adolescent population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1)11-17 years of age inclusive who have given their written assent and whose parents or legal guardians have given written at the time of enrollment;
2)who are available for all the visits scheduled in the study (i.e., not planning to leave the area before the end of the study period);
3)in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and two injections of placebo (at month 1, month 2). A second injection of rMenB+OMV NZ vaccine was given later (month 6).
Biological: rMenB+OMV NZ · Biological: Placebo
Subjects received one injection of rMenB+OMV NZ vaccine (month 0) and three injections of placebo (month 1, month 2 and month 6).
Biological: rMenB+OMV NZ · Biological: Placebo
Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
Biological: rMenB+OMV NZ · Biological: Placebo
Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 1) and two injection of placebo (at month 2 and month 6).
Biological: rMenB+OMV NZ · Biological: Placebo
Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and one injection of placebo (at month 2). A third injection of rMenB+OMV NZ vaccine was given later (at month 6).
Biological: rMenB+OMV NZ · Biological: Placebo
Subjects received two injections of rMenB+OMV NZ vaccine (at month 0 and month 2) and two injections of placebo (at month 1 and month 6).
Biological: rMenB+OMV NZ · Biological: Placebo
Subjects received three injections of rMenB+OMV NZ vaccine (at month 0, month 1 and month 2) and one injection of placebo later (at month 6).
Biological: rMenB+OMV NZ · Biological: Placebo
Subjects received three injections of placebo(at month 0, month 1 and month 2) and one injection of rMenB+OMV NZ vaccine(at month 6).
Biological: rMenB+OMV NZ · Biological: Placebo
Drug page: 4CMenB vaccine
Also known as: Serogroup B Meningococcal Vaccine
Percentages of Subjects With hSBA Titer ≥1:4 After Receiving One, Two or Three Doses of rMenB+OMV NZ Vaccine.
Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titter \>1:4 against 44/76-SL, 5/99, NZ98/254 strains at months 1, 2, 3.
Time frame: Month-1, 2, 3
Number of Subjects With Local Reactions and Systemic Reactions Occurring in Days 1 to 7 After Vaccination
Safety was assessed as the number of subjects who reported local and systemic reactions during day 1 to day 7 after any vaccination with rMenB+OMV
Time frame: 1 to 7 days after each vaccination
Percentages of Subjects With hSBA Titer ≥1:4 After Receiving a Booster Dose of rMenB+OMV NZ Vaccine at Month 6.
Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titter \>1:4 agains 44/76-SL, 5/99, NZ98/254 strains at months 6 \& 7.
Time frame: Month-6 & 7
Percentage of Subjects With hSBA Titer ≥1:8 After Primary and Booster Vaccination.
Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titer ≥1:8 against 44/76-SL, 5/99, NZ98/254 strains.
Time frame: at baseline, month-1, month-2, month-3, month-6 and month-7.
Percentages of Subjects With at Least a Fourfold Rise in hSBA Titer Over the Prevaccination and After Booster Vaccination.
Immunogenicity was evaluated by measuring the percentage of subjects with at least a fourfold rise in hSBA titer over the prevaccination and after booster vaccination against 44/76-SL, 5/99, NZ98/254 strains at month-1, month-2, month-3 and month-7.
Time frame: Month-1, month-2, month-3 and month-7
Geometric Mean Titers (GMTs) After Primary and Booster Vaccination.
Immunogenicity was evaluated by measuring the Geometric mean titers (GMTs) after primary and booster vaccination against 44/76-SL, 5/99, NZ98/254.
Time frame: month-1, month-2, month-3, month-6 and month-7
Geometric Mean Ratios (GMRs) After Primary and Booster Vaccination.
Immunogenicity was evaluated by measuring the Geometric mean ratios (GMRs) after primary and booster vaccination against 44/76-SL, 5/99, NZ98/254.
Time frame: month-1, month-2, month-3, month-6 and month-7
GMCs of Antibodies Against 287-953Antigen (ELISA) After Primary and Booster Vaccination.
Immunogenicity was evaluated by measuring the Geometric mean Concentration (GMCs) after primary and booster vaccination against Antigen 287-953 Antigen.
Time frame: month-1, month-2, month-3, month-6 and month-7
GMRs of Antibodies Against 287-953Antigen (ELISA) After Primary and Booster Vaccination
Immunogenicity was evaluated by measuring the Geometric mean Ratios (GMRs) after primary and booster vaccination against 287-953Antigen
Time frame: month-1, month-2, month-3, month-6 and month-7
Number of Subjects Reporting Unsolicited AEs Throughout the Study.
Safety was assessed as the number of subjects who reported unsolicited AEs throughout the study.
Time frame: Throughout the study
Subjects were enrolled at 10 study centers in Chile.
| Milestone | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| Started | 128 | 247 | 128 | 247 | 127 | 253 | 373 | 128 |
| Completed | 112 | 208 | 111 | 219 | 107 | 216 | 309 | 117 |
| Not completed | 16 | 39 | 17 | 28 | 20 | 37 | 64 | 11 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Unable to classify | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 6 | 3 | 3 | 0 | 2 | 2 | 1 |
| Withdrew: Withdrawal by subject | 11 | 25 | 12 | 21 | 12 | 26 | 45 | 9 |
| Withdrew: Lost to follow-up | 2 | 7 | 2 | 2 | 5 | 7 | 14 | 1 |
| Withdrew: Administrative reason | 0 | 1 | 0 | 2 | 2 | 2 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Inappropriate enrollment | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titter \>1:4 against 44/76-SL, 5/99, NZ98/254 strains at months 1, 2, 3.
| percentage of Subjects | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| 44/76-SL- Mo 0 | 42 (33 to 52) | 47 (40 to 54) | 41 (32 to 50) | 38 (32 to 45) | 37 (28 to 47) | 47 (40 to 53) | 46 (41 to 52) | 46 (36 to 55) |
| 44/76-SL- Mo 1 | 92 (85 to 96) | 92 (88 to 95) | 95 (89 to 98) | 93 (88 to 96) | 90 (83 to 95) | 92 (88 to 95) | 95 (92 to 97) | 43 (34 to 53) |
| 44/76-SL- Mo 2 | 88 (80 to 93) | 92 (88 to 95) | 100 (97 to 100) | 100 (98 to 100) | 88 (80 to 93) | 89 (85 to 93) | 100 (98 to 100) | 50 (40 to 59) |
| 44/76-SL- Mo 3 | 84 (76 to 90) | 88 (82 to 92) | 99 (95 to 100) | 100 (97 to 100) | 100 (97 to 100) | 100 (98 to 100) | 100 (98 to 100) | 48 (38 to 58) |
| 5/99- Mo 0 | 29 (20 to 38) | 41 (35 to 48) | 28 (20 to 38) | 31 (25 to 38) | 30 (22 to 39) | 37 (31 to 44) | 36 (30 to 41) | 29 (21 to 38) |
| 5/99- Mo 1 | 97 (92 to 99) | 96 (93 to 98) | 96 (90 to 99) | 97 (94 to 99) | 97 (92 to 99) | 95 (92 to 98) | 97 (94 to 98) | 35 (26 to 44) |
| 5/99- Mo 2 | 95 (90 to 98) | 94 (90 to 97) | 100 (97 to 100) | 100 (98 to 100) | 97 (92 to 99) | 96 (93 to 98) | 100 (98 to 100) | 31 (23 to 41) |
| 5/99- Mo 3 | 92 (85 to 96) | 89 (84 to 93) | 99 (95 to 100) | 100 (98 to 100) | 98 (93 to 100) | 100 (98 to 100) | 100 (99 to 100) | 32 (24 to 42) |
| NZ98/254-mo 0 | 32 (24 to 42) | 39 (33 to 46) | 33 (24 to 42) | 35 (29 to 41) | 34 (25 to 43) | 37 (31 to 44) | 33 (28 to 38) | 38 (29 to 47) |
| NZ98/254-mo 1 | 90 (83 to 95) | 94 (90 to 97) | 95 (89 to 98) | 94 (90 to 96) | 90 (83 to 95) | 93 (89 to 96) | 95 (92 to 97) | 38 (29 to 48) |
| NZ98/254-mo 2 | 81 (73 to 88) | 84 (74 to 88) | 99 (95 to 100) | 100 (98 to 100) | 78 (69 to 86) | 85 (79 to 89) | 100 (98 to 100) | 39 (29 to 48) |
| NZ98/254-mo 3 | 80 (72 to 87) | 76 (70 to 82) | 97 (92 to 99) | 97 (94 to 99) | 100 (97 to 100) | 100 (98 to 100) | 99 (97 to 100) | 43 (33 to 52) |
Safety was assessed as the number of subjects who reported local and systemic reactions during day 1 to day 7 after any vaccination with rMenB+OMV
| participants | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| erythema (local) | 93 | 162 | 95 | 188 | 94 | 172 | 282 | 85 |
| Induration (Local) | 71 | 130 | 75 | 151 | 82 | 121 | 228 | 57 |
| Swelling (Local) | 72 | 132 | 81 | 144 | 76 | 115 | 226 | 54 |
| Pain (Local) | 122 | 236 | 124 | 237 | 113 | 236 | 345 | 123 |
| Med.Att Fever (Systemic) | 1 | 0 | 2 | 0 | 1 | 1 | 1 | 1 |
| Malaise (Systemic) | 92 | 181 | 96 | 172 | 87 | 185 | 272 | 89 |
| Myalgia(Systemic) | 85 | 141 | 91 | 156 | 81 | 160 | 238 | 91 |
| Arthralgia(Systemic) | 55 | 76 | 55 | 80 | 39 | 105 | 146 | 43 |
| Headache(Systemic) | 79 | 139 | 88 | 160 | 73 | 165 | 244 | 74 |
| Nausea(Systemic) | 41 | 80 | 51 | 72 | 42 | 88 | 143 | 49 |
| Fever(Systemic) | 12 | 8 | 11 | 21 | 18 | 26 | 38 | 18 |
Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titter \>1:4 agains 44/76-SL, 5/99, NZ98/254 strains at months 6 \& 7.
| percentage of Subjects | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| 44/76-SL- Mo 6 | 76 (66 to 84) | 72 (65 to 79) | 93 (86 to 97) | 92 (88 to 96) | 97 (91 to 99) | 98 (94 to 99) | 97 (94 to 99) | 46 (36 to 56) |
| 44/76-SL- Mo 7 | 100 (96 to 100) | 71 (64 to 78) | 100 (96 to 100) | 90 (85 to 94) | 100 (96 to 100) | 95 (91 to 98) | 95 (92 to 98) | 93 (85 to 97) |
| 5/99- Mo 6 | 79 (70 to 87) | 74 (67 to 80) | 99 (95 to 100) | 98 (96 to 100) | 99 (95 to 100) | 100 (97 to 100) | 100 (98 to 100) | 28 (19 to 38) |
| 5/99- Mo 7 | 99 (94 to 100) | 67 (60 to 74) | 100 (96 to 100) | 98 (95 to 99) | 100 (96 to 100) | 99 (96 to 100) | 99 (97 to 100) | 93 (85 to 97) |
| NZ98/254-mo 6 | 81 (72 to 88) | 69 (62 to 76) | 93 (86 to 97) | 89 (84 to 93) | 97 (91 to 99) | 96 (92 to 98) | 97 (94 to 99) | 45 (35 to 55) |
| NZ98/254-mo 7 | 100 (96 to 100) | 67 (60 to 74) | 100 (96 to 100) | 85 (79 to 90) | 100 (96 to 100) | 94 (89 to 97) | 95 (92 to 98) | 93 (85 to 97) |
Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titer ≥1:8 against 44/76-SL, 5/99, NZ98/254 strains.
| percentage of Subjects | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| 44/76-SL- Mo 0 | 29 (21 to 39) | 37 (31 to 44) | 31 (23 to 40) | 32 (26 to 38) | 30 (22 to 39) | 35 (29 to 42) | 33 (28 to 38) | 33 (24 to 42) |
| 44/76-SL- Mo 1 | 87 (79 to 92) | 87 (82 to 91) | 85 (77 to 91) | 85 (80 to 89) | 81 (72 to 88) | 87 (82 to 91) | 86 (82 to 90) | 30 (22 to 40) |
| 44/76-SL- Mo 2 | 79 (70 to 86) | 84 (78 to 89) | 99 (95 to 100) | 99 (97 to 100) | 80 (71 to 87) | 80 (74 to 85) | 99 (98 to 100) | 33 (24 to 43) |
| 44/76-SL- Mo 3 | 74 (64 to 82) | 77 (71 to 83) | 99 (95 to 100) | 98 (95 to 99) | 99 (95 to 100) | 100 (98 to 100) | 99 (97 to 100) | 36 (27 to 46) |
| 44/76-SL- Mo 6 | 62 (52 to 72) | 62 (54 to 69) | 90 (82 to 95) | 83 (77 to 88) | 90 (82 to 95) | 91 (86 to 95) | 93 (90 to 96) | 34 (25 to 44) |
| 44/76-SL- Mo 7 | 99 (94 to 100) | 57 (49 to 64) | 100 (96 to 100) | 82 (75 to 87) | 100 (96 to 100) | 88 (82 to 92) | 91 (86 to 94) | 89 (81 to 95) |
| 5/99- Mo 0 | 18 (11 to 26) | 24 (19 to 30) | 20 (13 to 29) | 22 (17 to 28) | 23 (15 to 32) | 22 (17 to 28) | 22 (17 to 26) | 14 (8 to 21) |
| 5/99- Mo 1 | 96 (91 to 99) | 91 (87 to 95) | 89 (82 to 94) | 94 (90 to 96) | 91 (84 to 96) | 93 (89 to 96) | 94 (91 to 96) | 19 (12 to 28) |
| 5/99- Mo 2 | 89 (81 to 94) | 85 (80 to 90) | 100 (97 to 100) | 100 (98 to 100) | 78 (69 to 86) | 88 (83 to 92) | 99 (98 to 100) | 17 (11 to 26) |
| 5/99- Mo 3 | 81 (73 to 88) | 77 (71 to 83) | 99 (95 to 100) | 100 (97 to 100) | 98 (93 to 100) | 100 (98 to 100) | 100 (99 to 100) | 19 (12 to 27) |
| 5/99- Mo 6 | 60 (50 to 70) | 57 (50 to 64) | 97 (91 to 99) | 98 (95 to 99) | 98 (93 to 100) | 99 (96 to 100) | 99 (97 to 100) | 16 (9 to 25) |
| 5/99- Mo 7 | 99 (94 to 100) | 48 (40 to 56) | 100 (96 to 100) | 97 (93 to 99) | 100 (96 to 100) | 97 (94 to 99) | 98 (95 to 99) | 86 (78 to 93) |
| NZ98/254 Mo 0 | 22 (15 to 31) | 30 (24 to 36) | 27 (19 to 36) | 25 (20 to 31) | 24 (16 to 33) | 26 (21 to 32) | 25 (20 to 30) | 29 (21 to 38) |
| NZ98/254 Mo 1 | 84 (76 to 90) | 83 (77 to 87) | 82 (74 to 89) | 84 (79 to 88) | 75 (65 to 82) | 80 (74 to 85) | 86 (81 to 89) | 26 (18 to 35) |
| NZ98/254 Mo 2 | 72 (62 to 80) | 70 (64 to 76) | 98 (93 to 100) | 99 (97 to 100) | 65 (55 to 74) | 75 (68 to 80) | 99 (97 to 100) | 31 (23 to 41) |
| NZ98/254 Mo 3 | 70 (60 to 79) | 65 (58 to 71) | 90 (82 to 95) | 91 (86 to 94) | 98 (93 to 100) | 100 (97 to 100) | 98 (96 to 99) | 30 (21 to 39) |
| NZ98/254 Mo 6 | 60 (49 to 69) | 54 (47 to 62) | 80 (71 to 87) | 77 (70 to 82) | 86 (77 to 92) | 86 (80 to 90) | 91 (87 to 94) | 38 (28 to 48) |
| NZ98/254 Mo 7 | 99 (94 to 100) | 49 (42 to 57) | 99 (94 to 100) | 71 (64 to 78) | 100 (96 to 100) | 81 (74 to 86) | 84 (79 to 88) | 86 (78 to 93) |
Immunogenicity was evaluated by measuring the percentage of subjects with at least a fourfold rise in hSBA titer over the prevaccination and after booster vaccination against 44/76-SL, 5/99, NZ98/254 strains at month-1, month-2, month-3 and month-7.
| percentage of Subjects | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| 44/76-SL Mo 1 | 73 (64 to 81) | 75 (69 to 80) | 71 (61 to 79) | 77 (71 to 82) | 67 (58 to 76) | 73 (67 to 79) | 72 (67 to 77) | 3 (1 to 7) |
| 44/76-SL Mo 2 | 62 (52 to 71) | 67 (60 to 73) | 94 (88 to 98) | 96 (92 to 98) | 65 (55 to 74) | 61 (54 to 67) | 94 (91 to 97) | 6 (2 to 12) |
| 44/76-SL Mo 3 | 53 (43 to 63) | 59 (52 to 66) | 88 (81 to 94) | 91 (87 to 95) | 91 (84 to 96) | 95 (92 to 98) | 95 (92 to 97) | 3 (1 to 8) |
| 44/76-SL Mo 7 | 95 (89 to 99) | 33 (26 to 40) | 98 (93 to 100) | 73 (66 to 79) | 93 (86 to 98) | 76 (69 to 82) | 80 (75 to 85) | 76 (66 to 84) |
| 5/99 Mo 1 | 87 (80 to 93) | 79 (73 to 84) | 81 (72 to 87) | 85 (80 to 89) | 79 (70 to 86) | 85 (80 to 89) | 85 (80 to 88) | 3 (1 to 7) |
| 5/99 Mo 2 | 78 (69 to 85) | 65 (58 to 72) | 98 (93 to 100) | 98 (95 to 100) | 63 (53 to 72) | 74 (68 to 80) | 98 (96 to 99) | 5 (2 to 10) |
| 5/99 Mo 3 | 65 (56 to 74) | 53 (46 to 60) | 95 (89 to 98) | 99 (96 to 100) | 96 (91 to 99) | 99 (96 to 100) | 99 (98 to 100) | 6 (3 to 13) |
| 5/99- Mo 7 | 98 (92 to 100) | 27 (21 to 34) | 99 (94 to 100) | 88 (82 to 92) | 99 (94 to 100) | 90 (85 to 94) | 94 (90 to 97) | 82 (73 to 89) |
| NZ98/254 Mo 1 | 72 (63 to 80) | 70 (63 to 76) | 65 (56 to 74) | 74 (67 to 79) | 59 (49 to 68) | 64 (58 to 70) | 73 (68 to 78) | 3 (1 to 7) |
| NZ98/254 Mo 2 | 57 (47 to 67) | 52 (45 to 59) | 89 (81 to 94) | 93 (89 to 96) | 51 (41 to 61) | 57 (50 to 64) | 93 (89 to 95) | 7 (3 to 14) |
| NZ98/254 Mo 3 | 50 (40 to 59) | 43 (36 to 50) | 78 (69 to 85) | 81 (76 to 86) | 91 (84 to 96) | 91 (86 to 94) | 93 (90 to 96) | 6 (3 to 13) |
| NZ98/254 Mo 7 | 94 (87 to 98) | 27 (21 to 35) | 95 (88 to 98) | 62 (55 to 69) | 92 (85 to 97) | 69 (62 to 76) | 75 (69 to 80) | 77 (67 to 85) |
Immunogenicity was evaluated by measuring the Geometric mean titers (GMTs) after primary and booster vaccination against 44/76-SL, 5/99, NZ98/254.
| Titers | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| 44/76 GMT Mo 0 | 3.41 (2.54 to 4.58) | 4.24 (3.44 to 5.22) | 3.34 (2.49 to 4.48) | 3.35 (2.72 to 4.11) | 3.39 (2.52 to 4.56) | 3.99 (3.25 to 4.9) | 3.87 (3.26 to 4.6) | 3.89 (2.91 to 5.19) |
| 44/76 GMT Mo 1 | 46 (33 to 63) | 58 (46 to 72) | 56 (40 to 77) | 52 (41 to 65) | 44 (32 to 61) | 57 (45 to 71) | 60 (49 to 72) | 3.39 (2.46 to 4.65) |
| 44/76 GMT Mo 2 | 31 (23 to 41) | 41 (34 to 50) | 182 (138 to 240) | 187 (154 to 228) | 28 (21 to 37) | 38 (31 to 46) | 193 (164 to 228) | 4.09 (3.11 to 5.38) |
| 44/76 GMT Mo 3 | 20 (16 to 26) | 31 (26 to 38) | 132 (101 to 172) | 114 (95 to 137) | 182 (139 to 236) | 230 (191 to 277) | 240 (205 to 280) | 4.04 (3.12 to 5.22) |
| 44/76 GMT Mo 6 | 13 (9.24 to 18) | 15 (12 to 19) | 59 (43 to 82) | 50 (39 to 63) | 54 (39 to 75) | 75 (60 to 95) | 86 (70 to 104) | 3.9 (2.82 to 5.4) |
| 44/76 GMT Mo 7 | 218 (157 to 302) | 12 (9.69 to 15) | 324 (236 to 443) | 36 (29 to 45) | 259 (188 to 357) | 48 (38 to 60) | 59 (49 to 72) | 56 (41 to 77) |
| 5/99 GMT Mo 0 | 2.61 (2.03 to 3.34) | 3.15 (2.64 to 3.75) | 2.59 (2.02 to 3.32) | 2.52 (2.11 to 2.99) | 2.43 (1.89 to 3.12) | 2.72 (2.29 to 3.24) | 2.58 (2.23 to 2.98) | 2.27 (1.78 to 2.89) |
| 5/99 GMT Mo 1 | 81 (61 to 109) | 64 (52 to 79) | 66 (49 to 88) | 72 (59 to 88) | 57 (42 to 76) | 76 (62 to 93) | 71 (60 to 84) | 2.56 (1.93 to 3.4) |
| 5/99 GMT Mo 2 | 40 (31 to 51) | 34 (28 to 40) | 505 (396 to 644) | 451 (381 to 535) | 26 (20 to 33) | 40 (34 to 48) | 481 (415 to 556) | 2.48 (1.95 to 3.16) |
| 5/99 GMT Mo 3 | 25 (20 to 31) | 23 (20 to 27) | 303 (242 to 380) | 273 (233 to 320) | 540 (431 to 677) | 822 (702 to 964) | 584 (510 to 668) | 2.58 (2.07 to 3.22) |
| 5/99 GMT Mo 6 | 12 (9.56 to 16) | 11 (9.26 to 13) | 125 (98 to 160) | 113 (95 to 135) | 124 (97 to 158) | 147 (123 to 175) | 186 (160 to 216) | 2.03 (1.59 to 2.59) |
| 5/99 GMT Mo 7 | 880 (675 to 1147) | 8.61 (7.13 to 10) | 1094 (849 to 1410) | 99 (82 to 119) | 994 (767 to 1289) | 121 (101 to 146) | 164 (141 to 192) | 53 (41 to 68) |
| NZ98/254 GMT Mo 0 | 2.87 (2.14 to 3.84) | 3.35 (2.72 to 4.13) | 3.43 (2.56 to 4.59) | 2.98 (2.43 to 3.66) | 3.07 (2.28 to 4.12) | 3.39 (2.76 to 4.16) | 2.83 (2.38 to 3.36) | 3.12 (2.34 to 4.15) |
| NZ98/254 GMT Mo1 | 42 (31 to 56) | 44 (36 to 55) | 47 (35 to 63) | 45 (36 to 55) | 37 (27 to 50) | 42 (34 to 52) | 49 (41 to 58) | 2.85 (2.11 to 3.84) |
| NZ98/254 GMT Mo 2 | 23 (17 to 30) | 25 (20 to 31) | 98 (72 to 132) | 89 (72 to 110) | 19 (14 to 26) | 26 (21 to 32) | 92 (77 to 110) | 3.28 (2.43 to 4.41) |
| NZ98/254 GMT Mo 3 | 17 (13 to 22) | 19 (16 to 24) | 61 (46 to 82) | 52 (42 to 64) | 117 (87 to 157) | 125 (102 to 154) | 122 (102 to 145) | 3.57 (2.68 to 4.75) |
| NZ98/254 GMT Mo 6 | 12 (8.94 to 17) | 11 (8.63 to 14) | 31 (22 to 42) | 29 (23 to 36) | 44 (32 to 61) | 49 (39 to 61) | 52 (43 to 63) | 4.17 (3.04 to 5.72) |
| NZ98/254 GMT Mo 7 | 140 (101 to 195) | 10 (8.01 to 13) | 181 (132 to 248) | 24 (19 to 30) | 168 (122 to 232) | 39 (31 to 49) | 41 (34 to 50) | 47 (34 to 64) |
Immunogenicity was evaluated by measuring the Geometric mean ratios (GMRs) after primary and booster vaccination against 44/76-SL, 5/99, NZ98/254.
| Ratio | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| 44/76 GMR Mo 1 to 0 | 13 (10 to 18) | 14 (11 to 17) | 17 (12 to 22) | 16 (13 to 19) | 13 (9.71 to 18) | 14 (12 to 17) | 15 (13 to 18) | 0.89 (0.66 to 1.18) |
| 44/76 GMR Mo 2 to 0 | 8.92 (6.73 to 12) | 9.65 (7.88 to 12) | 53 (40 to 71) | 56 (46 to 69) | 8.43 (6.33 to 11) | 9.51 (7.79 to 12) | 50 (42 to 59) | 1.04 (0.79 to 1.38) |
| 44/76 GMR Mo 3 to 0 | 5.98 (4.51 to 7.92) | 7.31 (5.97 to 8.96) | 37 (28 to 50) | 34 (28 to 42) | 55 (41 to 73) | 58 (48 to 71) | 62 (52 to 73) | 0.98 (0.74 to 1.3) |
| 44/76 GMR Mo 6 to 0 | 3.98 (2.96 to 5.35) | 3.64 (2.93 to 4.52) | 17 (13 to 23) | 16 (13 to 19) | 16 (12 to 21) | 20 (16 to 25) | 23 (19 to 27) | 0.92 (0.69 to 1.24) |
| 44/76 GMR Mo 7 to 0 | 74 (54 to 103) | 3.09 (2.46 to 3.88) | 92 (67 to 125) | 12 (9.24 to 14) | 79 (58 to 109) | 13 (11 to 17) | 16 (13 to 19) | 13 (9.76 to 18) |
| 44/76 GMR Mo 7 to 6 | 18 (14 to 23) | 0.89 (0.76 to 1.05) | 5.36 (4.3 to 6.68) | 0.72 (0.61 to 0.84) | 5.08 (4.05 to 6.37) | 0.67 (0.57 to 0.79) | 0.67 (0.59 to 0.77) | 14 (11 to 17) |
| 5/99 GMR Mo 1 to 0 | 31 (23 to 42) | 20 (16 to 25) | 25 (19 to 34) | 29 (23 to 35) | 23 (17 to 32) | 28 (23 to 34) | 28 (23 to 33) | 1.13 (0.84 to 1.52) |
| 5/99 GMR Mo 2 to 0 | 15 (11 to 20) | 11 (8.65 to 13) | 198 (149 to 262) | 181 (149 to 220) | 11 (8.13 to 14) | 15 (12 to 18) | 186 (158 to 220) | 1.06 (0.8 to 1.4) |
| 5/99 GMR Mo 3 to 0 | 9.22 (6.94 to 12) | 7.37 (6.01 to 9.04) | 115 (86 to 153) | 109 (89 to 133) | 233 (175 to 311) | 306 (250 to 374) | 225 (190 to 267) | 1.09 (0.82 to 1.44) |
| 5/99 GMR Mo 6 to 0 | 4.65 (3.47 to 6.23) | 3.83 (3.09 to 4.75) | 49 (37 to 66) | 45 (36 to 55) | 52 (39 to 70) | 56 (45 to 69) | 74 (62 to 88) | 0.82 (0.61 to 1.1) |
| 5/99 GMR Mo 7 to 0 | 355 (254 to 497) | 3.07 (2.42 to 3.89) | 430 (312 to 594) | 40 (32 to 50) | 427 (307 to 593) | 46 (36 to 58) | 65 (53 to 79) | 21 (16 to 29) |
| 5/99 GMR Mo 7 to 6 | 71 (55 to 90) | 0.83 (0.7 to 0.99) | 8.98 (7.13 to 11) | 0.87 (0.74 to 1.03) | 7.92 (6.26 to 10) | 0.83 (0.71 to 0.99) | 0.86 (0.74 to 0.99) | 26 (20 to 32) |
| NZ98/254 GMR Mo 1 to 0 | 14 (11 to 19) | 13 (11 to 16) | 14 (10 to 18) | 15 (12 to 18) | 12 (9 to 16) | 12 (10 to 15) | 17 (15 to 21) | 0.91 (0.68 to 1.2) |
| NZ98/254 GMR Mo 2 to 0 | 7.69 (5.86 to 10) | 7.24 (5.97 to 8.79) | 29 (22 to 38) | 30 (24 to 36) | 6.46 (4.91 to 8.5) | 7.96 (6.57 to 9.63) | 33 (28 to 39) | 1.06 (0.81 to 1.38) |
| NZ98/254 GMR Mo 3 to 0 | 6.01 (4.54 to 7.96) | 5.5 (4.49 to 6.74) | 18 (14 to 24) | 18 (14 to 21) | 40 (30 to 54) | 38 (32 to 47) | 44 (37 to 52) | 1.13 (0.86 to 1.5) |
| NZ98/254 GMR Mo 6 to 0 | 4.75 (3.62 to 6.24) | 3.49 (2.86 to 4.26) | 9.26 (7.05 to 12) | 10 (8.29 to 12) | 14 (11 to 19) | 15 (13 to 19) | 19 (16 to 22) | 1.28 (0.98 to 1.68) |
| NZ98/254 GMR Mo 7 to 0 | 59 (44 to 80) | 3.32 (2.67 to 4.12) | 53 (40 to 71) | 8.94 (7.26 to 11) | 57 (42 to 77) | 13 (10 to 16) | 15 (12 to 18) | 15 (11 to 19) |
| NZ98/254 GMR Mo 7 to 6 | 11 (8.73 to 14) | 0.99 (0.84 to 1.17) | 5.86 (4.7 to 7.3) | 0.85 (0.73 to 1) | 3.95 (3.15 to 4.95) | 0.84 (0.72 to 0.99) | 0.81 (0.7 to 0.92) | 11 (8.98 to 14) |
Immunogenicity was evaluated by measuring the Geometric mean Concentration (GMCs) after primary and booster vaccination against Antigen 287-953 Antigen.
| IU/ml | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| GMC Mo 0 | 35 (25 to 51) | 35 (25 to 50) | 43 (30 to 61) | 37 (26 to 54) | 44 (31 to 63) | 32 (23 to 46) | 32 (22 to 45) | 48 (34 to 68) |
| GMC Mo 1 | 190 (113 to 318) | 204 (123 to 340) | 334 (200 to 555) | 217 (130 to 361) | 234 (140 to 389) | 220 (132 to 367) | 521 (313 to 868) | 50 (30 to 82) |
| GMC Mo 2 | 173 (115 to 261) | 154 (102 to 231) | 3025 (2015 to 4543) | 3875 (2566 to 5854) | 175 (117 to 263) | 144 (96 to 216) | 3693 (2459 to 5545) | 42 (28 to 62) |
| GMC Mo 3 | 102 (69 to 152) | 124 (84 to 183) | 1612 (1093 to 2378) | 1831 (1234 to 2716) | 3332 (2259 to 4916) | 2936 (1990 to 4332) | 5314 (3602 to 7839) | 42 (29 to 62) |
| GMC Mo 6 | 91 (59 to 138) | 72 (48 to 110) | 565 (372 to 857) | 488 (322 to 741) | 807 (531 to 1224) | 628 (414 to 953) | 1602 (1055 to 2431) | 37 (24 to 56) |
| GMC Mo 7 | 2240 (1385 to 3623) | 69 (43 to 112) | 3840 (2391 to 6168) | 383 (237 to 620) | 5492 (3419 to 8821) | 532 (331 to 855) | 1111 (692 to 1785) | 283 (176 to 454) |
Immunogenicity was evaluated by measuring the Geometric mean Ratios (GMRs) after primary and booster vaccination against 287-953Antigen
| Ratio | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| GMR Mo 1 to 0 | 5.73 (3.19 to 9.05) | 5.82 (3.48 to 9.73) | 7.75 (4.64 to 13) | 5.34 (3.12 to 9.14) | 5.26 (3.14 to 8.79) | 6.85 (4.09 to 11) | 16 (9.77 to 27) | 1.03 (0.62 to 1.73) |
| GMR Mo 2 to 0 | 4.9 (3.2 to 7.5) | 4.38 (2.88 to 6.66) | 70 (46 to 107) | 112 (72 to 175) | 3.94 (2.59 to 5.99) | 4.46 (2.93 to 6.79) | 116 (76 to 176) | 0.87 (0.57 to 1.32) |
| GMR Mo 3 to 0 | 2.9 (1.82 to 4.61) | 3.54 (2.24 to 5.59) | 37 (24 to 59) | 55 (34 to 89) | 75 (47 to 118) | 91 (58 to 144) | 167 (105 to 263) | 0.88 (0.56 to 1.4) |
| GMR Mo 6 to 0 | 2.56 (1.59 to 4.13) | 2.06 (1.29 to 3.3) | 13 (8.2 to 21) | 13 (7.86 to 21) | 18 (11 to 29) | 20 (12 to 31) | 50 (31 to 80) | 0.77 (0.48 to 1.23) |
| GMR Mo 7 to 0 | 63 (34 to 119) | 1.94 (1.03 to 3.64) | 89 (48 to 166) | 11 (5.67 to 21) | 123 (66 to 229) | 17 (8.9 to 31) | 35 (19 to 65) | 5.9 (3.17 to 11) |
Safety was assessed as the number of subjects who reported unsolicited AEs throughout the study.
| participants | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| Any AE's | 65 | 137 | 73 | 143 | 72 | 148 | 210 | 80 |
| At least possibly related AEs | 22 | 36 | 30 | 36 | 24 | 43 | 76 | 26 |
| Serious AEs | 5 | 4 | 2 | 4 | 2 | 4 | 11 | 3 |
| At least possibly related SAEs | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 |
| AEs leading to discontinuation | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 |
Immunogenicity was evaluated by measuring the percentage of subjects with hSBA titter \>1:4 against M10713 strain at 1 month after second dose of vaccination (Month 3)
| Percentage of subjects | rMenB01 | rMenB02 |
|---|---|---|
| Baseline | 96 (85 to 99) | 80 (66 to 91) |
| 1 month after second dose | 100 (92 to 100) | 100 (92 to 100) |
Collected over Solicited adverse events (AEs) were collected from Day 1 through 7,Serious AEs were collected throughout the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rMenB06 | — | 5/128 (3.9%) | 123/128 (96.1%) |
| rMenB0 | — | 4/247 (1.6%) | 238/247 (96.4%) |
| rMenB016 | — | 2/128 (1.6%) | 126/128 (98.4%) |
| rMenB01 | — | 4/247 (1.6%) | 242/247 (98%) |
| rMenB026 | — | 2/127 (1.6%) | 118/127 (92.9%) |
| rMenB02 | — | 4/253 (1.6%) | 240/253 (94.9%) |
| rMenB012 | — | 11/373 (2.9%) | 354/373 (94.9%) |
| rMenB6 | — | 3/128 (2.3%) | 125/128 (97.7%) |
| Event | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| TOXICITY TO VARlOUS AGENTSInjury, poisoning and procedural complications | 0/128 | 0/247 | 0/128 | 0/247 | 0/127 | 2/253 | 0/373 | 0/128 |
| APPENDICITISInfections and infestations | 1/128 | 1/247 | 1/128 | 1/247 | 1/127 | 1/253 | 2/373 | 1/128 |
| MAJOR DEPRESSIONPsychiatric disorders | 0/128 | 0/247 | 0/128 | 0/247 | 1/127 | 0/253 | 0/373 | 0/128 |
| PANIC ATTACKPsychiatric disorders | 0/128 | 0/247 | 0/128 | 0/247 | 1/127 | 0/253 | 0/373 | 0/128 |
| SUICIDE ATTEMPTPsychiatric disorders | 0/128 | 1/247 | 0/128 | 0/247 | 1/127 | 0/253 | 0/373 | 1/128 |
| PNEUMONIA VIRALInfections and infestations | 1/128 | 0/247 | 0/128 | 0/247 | 0/127 | 0/253 | 0/373 | 0/128 |
| ROAD TRAFFIC ACCIDENTInjury, poisoning and procedural complications | 1/128 | 0/247 | 0/128 | 0/247 | 0/127 | 0/253 | 0/373 | 0/128 |
| ADENOMA BENIGNNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/128 | 0/247 | 0/128 | 0/247 | 0/127 | 0/253 | 0/373 | 1/128 |
| CONVULSIONNervous system disorders | 1/128 | 1/247 | 0/128 | 0/247 | 0/127 | 0/253 | 0/373 | 0/128 |
| PREMATURE LABOURPregnancy, puerperium and perinatal conditions | 1/128 | 0/247 | 1/128 | 0/247 | 0/127 | 0/253 | 0/373 | 0/128 |
| Event | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 |
|---|---|---|---|---|---|---|---|---|
| INJECTION SITE PAINGeneral disorders | 122/128 | 236/247 | 124/128 | 237/247 | 113/127 | 236/253 | 345/373 | 123/128 |
| INJECTION SITE ERYTHEMAGeneral disorders | 93/128 | 162/247 | 97/128 | 188/247 | 94/127 | 172/253 | 282/373 | 86/128 |
| MALAISEGeneral disorders | 92/128 | 181/247 | 96/128 | 172/247 | 87/127 | 185/253 | 272/373 | 89/128 |
| MYALGIAMusculoskeletal and connective tissue disorders | 85/128 | 141/247 | 91/128 | 158/247 | 82/127 | 160/253 | 238/373 | 91/128 |
| HEADACHENervous system disorders | 79/128 | 140/247 | 88/128 | 160/247 | 74/127 | 165/253 | 244/373 | 76/128 |
| INJECTION SITE INDURATIONGeneral disorders | 72/128 | 130/247 | 76/128 | 151/247 | 82/127 | 122/253 | 228/373 | 58/128 |
| INJECTION SITE SWELLINGGeneral disorders | 73/128 | 132/247 | 81/128 | 144/247 | 76/127 | 115/253 | 226/373 | 55/128 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 56/128 | 76/247 | 55/128 | 81/247 | 39/127 | 105/253 | 146/373 | 44/128 |
| NAUSEAGastrointestinal disorders | 41/128 | 80/247 | 51/128 | 72/247 | 42/127 | 89/253 | 143/373 | 49/128 |
| PYREXIAGeneral disorders | 12/128 | 8/247 | 13/128 | 21/247 | 18/127 | 26/253 | 38/373 | 20/128 |
| Age, Continuous(years) | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 13.8 ± 1.9 | 13.8 ± 1.9 | 13.9 ± 1.9 | 13.9 ± 1.9 | 13.7 ± 1.9 | 13.7 ± 1.8 | 13.8 ± 1.9 | 13.8 ± 2 | 13.8 ± 1.9 |
| Sex: Female, Male(Participants) | rMenB06 | rMenB0 | rMenB016 | rMenB01 | rMenB026 | rMenB02 | rMenB012 | rMenB6 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 76 | 147 | 76 | 138 | 73 | 138 | 199 | 66 | 913 |
| Male | 52 | 100 | 52 | 109 | 54 | 115 | 174 | 62 | 718 |
The record gives a start of Jun 2008, a primary completion of Apr 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 5 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 4CMenB vaccine